We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
The A29L protein, a key component in the monkeypox virus (MPXV) lifecycle, plays a crucial role in immune evasion and viral replication. Targeting A29L offers promising potential for advancing both diagnostic and therapeutic research. Creative Biolabs specializes in providing tailored antibody development services targeting A29L, offering high-quality solutions for researchers focused on monkeypox and related viruses.
A29L is classified as part of the MPXV virion's structure and functions primarily as an immune evasion mechanism. In particular, A29L has been identified as a key factor in the virus's ability to subvert host immune responses. By modulating the host immune system, A29L helps the virus evade detection and clearance by the immune system, making it an attractive target for therapeutic and diagnostic strategies. Recent studies have highlighted the importance of A29L in the pathogenesis of monkeypox, showing that it is involved in both viral replication and immune modulation. As a target for antibody development, A29L offers great potential for improving our ability to diagnose and manage monkeypox infections.
Creative Biolabs offers comprehensive antibody development services tailored to the specific needs of researchers working with monkeypox and other related viruses. Our A29L antibody development pipeline is designed to provide high-quality, custom antibodies that can effectively target this key viral protein.
The first step in antibody development is the identification and validation of the A29L protein as a reliable target. This involves extensive research and screening to ensure that A29L is a suitable biomarker for immune response in monkeypox infections.
Following target validation, the next step is the selection of lead antibody candidates. This is achieved through the screening of large antibody libraries to identify promising candidates that show strong binding affinity to the A29L protein.
After lead antibody candidates are identified, the next phase involves optimizing their binding affinity to the A29L target. Using advanced techniques such as phage display and mammalian cell-based systems, antibodies are subjected to iterative rounds of affinity maturation to enhance their potency and specificity.
In order to enhance the therapeutic potential of the antibodies, we employ humanization techniques that minimize immunogenicity in research settings. This step is crucial for ensuring that the developed antibodies are well-tolerated by human immune systems, making them suitable for diagnostic applications or preclinical studies.
We offer both monoclonal antibodies and bispecific antibodies against the A29L target, providing a range of versatile solutions for various research needs. Our advanced custom antibody services, including high-throughput screening and rapid turnaround times, allow us to meet the specific requirements of any research project.
Creative Biolabs' ability to rapidly generate highly specific and potent antibodies makes us a trusted partner in the field of antibody development for monkeypox and other infectious diseases.
The A29L protein has a multifaceted role in the monkeypox virus lifecycle, influencing various stages of infection. Upon viral entry into the host cell, A29L helps the virus evade immune detection, particularly by interfering with the host's immune surveillance mechanisms. This immune modulation is crucial for the virus to establish infection and replicate in host tissues.
Antibodies targeting A29L can disrupt these processes, either by preventing the virus from evading the immune system or by enhancing the host's immune response to the infection. By neutralizing the A29L protein, these antibodies could hinder viral replication, potentially reducing the severity and duration of the infection. Furthermore, they may enhance the host immune response, promoting quicker resolution of the infection.
Given its role in immune evasion and viral replication, A29L represents an attractive target for antibody-based interventions. These antibodies could potentially play a pivotal role in mitigating the effects of monkeypox and other related orthopoxvirus infections.
| Cat# | Product Name | Target | Antibody Isotype | Species Reactivity | Applications |
|---|---|---|---|---|---|
| MPYF-1022-KX1633 | Anti-Variola (Smallpox) Virus A29L Monoclonal Antibody (MP-K1567) (Mouse IgG) | A29L | Mouse IgG | Variola (Smallpox) Virus | WB (Other applications need to be tested) |
| MPYF-1022-KX874 | Anti-Monkeypox Virus A29L Monoclonal Antibody (IgM) | A29L | IgM | Monkeypox Virus | - |
| MPYF-0822-YF21 | Anti-Monkeypox Virus A29L Monoclonal Antibody (MP-X21) (Mouse IgG2a, Lambda) | A29L | Mouse IgG2a, Lambda | Monkeypox Virus | Neut, ELISA |
| MPYF-1122-KX1596 | Anti-Squirrel Parapoxvirus A29L Monoclonal Antibody (MP-K2396) (Mouse IgG) | A29L | Mouse IgG | Squirrel Parapoxvirus | WB (Other applications need to be tested) |
| MPYF-1022-KX876 | Anti-Monkeypox Virus A29L Antibody Pair (B4-39) | A29L | Antibody Pair | Monkeypox Virus | - |
| MPYF-1022-KX1491 | Anti-Vaccinia Virus (Smallpox Vaccine) A29L Monoclonal Antibody (MP-K1425) (Mouse IgG) | A29L | Mouse IgG | Vaccinia Virus (Smallpox Vaccine) | WB (Other applications need to be tested) |
| MPYF-1022-KX873 | Anti-Monkeypox Virus A29L Monoclonal Antibody (IgG) | A29L | IgG | Monkeypox Virus | - |
| MPYF-0822-YF117 | Anti-Monkeypox Virus A29L Monoclonal Antibody (MP-W82) (Mouse IgG) | A29L | Mouse IgG | Monkeypox Virus | WB (Other applications need to be tested) |
| MPYF-0822-YF37 | Anti-Monkeypox Virus A29L Monoclonal Antibody (MP-X37) (Mouse IgG2a, Lambda) | A29L | Mouse IgG2a, Lambda | Monkeypox Virus | ELISA |
| Cat# | Product Name | Species | Expression System | Target Protein | Protein Length |
|---|---|---|---|---|---|
| MPYF-0922-KX768 | Magic™ Variola (Smallpox) Virus A29L Recombinant Protein | Variola (Smallpox) Virus | Based on specific requirements | A29L | Full length |
| MPYF-0722-KX22 | Magic™ Monkeypox virus A29L Recombinant Protein Expressed in E. coli | Monkeypox virus | E. coli | A29L | ECD |
| MPYF-0722-KX242 | Magic™ Monkeypox virus (Zaire-96-1-16) A29L Recombinant Protein | Monkeypox virus | Based on specific requirements | A29L | Full length |
| MPYF-1022-KX752 | Magic™ Squirrel Parapoxvirus (Red squirrel UK) A29L Recombinant Protein | Squirrel Parapoxvirus | Based on specific requirements | A29L | Full length |
| MPYF-0922-KX626 | Magic™ Vaccinia Virus (Smallpox Vaccine) (Western Reserve) A29L Recombinant Protein | Vaccinia Virus (Smallpox Vaccine) | Based on specific requirements | A29L | Full length |
| MPYF-0722-KX4 | Magic™ Monkeypox virus (Zaire-96-1-16) A29L Recombinant Protein Expressed in HEK293 | Monkeypox virus | HEK293 | A29L | Full length |
| Cat# | Product Name | Usage |
|---|---|---|
| MPYF-1022-KX1735 | Monkeypox virus A29L antigen latex microsphere immunochromatography | RUO |
| MPYF-1022-KX1734 | Monkeypox virus A29L antigen colloidal gold immunochromatography | RUO |
| Cat# | Product Name | Species | Target |
|---|---|---|---|
| MPYF-0722-KX1635 | Monkeypox virus, A29L-R | Monkeypox virus | A29L |
| MPYF-0722-KX1444 | Monkeypox virus, A29L-F | Monkeypox virus | A29L |
| Cat# | Product Name | Species | Target |
|---|---|---|---|
| MPYF-0722-KX1253 | Magic™ Monkeypox virus A29L Expression Plasmid | Monkeypox virus | A29L |
Creative Biolabs leverages a diverse range of cutting-edge platforms and technologies for A29L antibody development, ensuring the highest level of quality and efficiency in every project.
Hybridoma technology remains one of the most effective methods for generating monoclonal antibodies. By fusing B cells from immunized animals with myeloma cells, hybridoma technology enables the production of stable, high-affinity antibodies against A29L. This method guarantees a reliable source of monoclonal antibodies with the required specificity and binding affinity.
Phage display technology enables the creation of vast libraries of antibodies, which can be screened against the A29L protein to identify optimal candidates. This system allows us to rapidly isolate antibodies that exhibit the best binding properties and specificity, thus accelerating the antibody discovery process.
To ensure that antibodies are produced in biologically relevant systems, we utilize mammalian cell expression platforms. These systems enable the production of fully glycosylated antibodies, ensuring that the antibodies retain their functional properties. This is especially important for the humanization of monoclonal antibodies to reduce potential immunogenicity.
A29L antibodies have significant potential in both the diagnosis and research of monkeypox and other orthopoxviruses. These antibodies can be used in diagnostic assays such as ELISA or lateral flow tests to quickly and accurately detect monkeypox infections by binding to the A29L protein. Additionally, while A29L antibodies are not directly involved in vaccine development, they can play a critical role in evaluating immune responses during vaccine research. By using these antibodies, researchers can assess how effectively a vaccine stimulates an immune response against the A29L protein, providing valuable insights into its potential for preventing monkeypox.
Creative Biolabs is a leader in antibody development with over a decade of experience, offering advanced solutions tailored to researchers studying monkeypox and other viral infections.
With years of experience in viral antigen research, including orthopoxviruses like monkeypox, our team has the expertise to meet your unique project needs for diagnostics, research, and preclinical studies.
We prioritize quality at every stage of the antibody development process, from screening to final validation, ensuring our antibodies meet the highest standards of specificity and reliability.
Our track record speaks for itself, with successful collaborations across biotechnology, pharmaceutical, and academic sectors. Creative Biolabs delivers high-quality, custom antibodies with fast turnaround times, making us a trusted partner in advancing research.
Yes, Creative Biolabs offers fully customizable antibody development services, allowing us to tailor the A29L antibodies for a variety of applications, including diagnostics, research assays, and preclinical studies.
Yes, Creative Biolabs offers scalable antibody production services. We can support both small and large-scale production, ensuring that researchers have the quantities needed for their studies.
Absolutely. Creative Biolabs can produce monoclonal antibodies, bispecific antibodies, and other formats to meet the specific needs of your project, whether it's for enhanced specificity, dual-target applications, or other requirements.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.